Arthritis
E2F decoy ODN may provide useful approach for treatment of joint destruction in arthritis
Published in Immunotherapy Weekly, October 11th, 2006
"This study examined the ability of E2F decoy oligodeoxynucleotides to inhibit proliferation of synovial fibroblasts derived from patients with rheumatoid arthritis (RA). The effect of E2F decoy ODN on cartilage invasion by RA synovium in a murine model of human RA was also investigated," scientists writing in the International Journal of Molecular Medicine reported.
"E2F decoy ODN were introduced into synovial tissue and synovial fibroblasts derived...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2006-10-11)
More Articles from Immunotherapy Weekly
- Allergy & Immunology
High-intensity ultrasound reduces allergenic properties of shrimp allergens - Allergy & Immunology
Lymphoblast and T helper cell proliferation affected by interleukin - Arthritis
Arthritic erosion is hindered by thrombospondin-1 peptide - Systemic Lupus Erythematosus
Systemic lupus erythematosus gene mutation linked to autoimmune diseases - Allergy & Immunology
Education leads to decrease in the use of antibiotics as a frontline therapy for sinusitis - Allergy & Immunology
Endoscopic sinus surgery confirmed as an effective treatment for chronic rhinosinusitis - More from this issue of Immunotherapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
